Results 121 to 130 of about 16,069 (214)
Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.Abstract Background and aims
The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama +12 morewiley +1 more sourceConnecting the dots: A narrative review of the relationship between heart failure and cognitive impairment
ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.Abstract
Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...Mauro Massussi, Maria Giulia Bellicini, Marianna Adamo, Andrea Pilotto, Marco Metra, Alessandro Padovani, Riccardo Proietti +6 morewiley +1 more sourceMayo normative studies: regression-based normative data for ages 30-91 years with a focus on the Boston Naming Test, Trail Making Test and Category Fluency. [PDF]
J Int Neuropsychol SocKarstens AJ, Christianson TJ, Lundt ES, Machulda MM, Mielke MM, Fields JA, Kremers WK, Graff-Radford J, Vemuri P, Jack CR, Knopman DS, Petersen RC, Stricker NH. +12 moreeuropepmc +1 more sourceCardiLect: A combined cross‐species lectin histochemistry protocol for the automated analysis of cardiac remodelling
ESC Heart Failure, Volume 12, Issue 2, Page 1398-1415, April 2025.Abstract Background
Cardiac remodelling, a crucial aspect of heart failure, is commonly investigated in preclinical models by quantifying cardiomyocyte cross‐sectional area (CSA) and microvascular density (MVD) via histological methods, such as immunohistochemistry.Tamás G. Gergely, Tamás Kovács, Andrea Kovács, Viktória E. Tóth, Nabil V. Sayour, Gábor M. Mórotz, Csenger Kovácsházi, Gábor B. Brenner, Zsófia Onódi, Balázs Enyedi, Domokos Máthé, Przemyslaw Leszek, Zoltán Giricz, Péter Ferdinandy, Zoltán V. Varga +14 morewiley +1 more sourcePreoperative limbic cortical thinning in mesial temporal lobe epilepsy surgical candidates is associated with pre‐existing and de novo postoperative depression
Epileptic Disorders, EarlyView.Abstract Objective
Depression is common in mesial temporal lobe epilepsy (mTLE), but its neuroanatomical basis—and overlap with major depressive disorder (MDD)—remains poorly defined. We investigated whether the cortical and subcortical alterations reported in MDD are also present in mTLE and leveraged the frequent occurrence of depression after ...Philip Fink‐Jensen, Brice Ozenne, Ane Kloster, Bo Jespersen, Kirsten Vinter, Guido Rubboli, Martin Balslev Jørgensen, Sandor Beniczky, Melanie Ganz, Lars Hageman Pinborg +9 morewiley +1 more sourceResponsive stimulation of the thalamus for idiopathic generalized epilepsy: Results of the randomized controlled NAUTILUS trial through 18 months
Epilepsia, EarlyView.Abstract Objective
This study was undertaken to evaluate the safety and effectiveness of responsive thalamic stimulation as adjunctive therapy for drug‐resistant idiopathic generalized epilepsy (IGE) with generalized tonic–clonic seizures (GTCSs). Methods
NAUTILUS is a prospective, multicenter, single‐blind, randomized sham‐controlled pivotal trial ...Utku Uysal, Patrick Landazuri, David E. Burdette, Sanjay Patra, Angela N. Crudele, Dario J Englot, Jay R. Gavvala, Sandipan Pati, Lesley C. Kaye, Steven Ojemann, Daniel Barnett, Joseph Neimat, Adriana E. Palade, Shervin Rahimpour, Amir A. Arain, Robert Mark Richardson, Sydney S. Cash, Vicenta Salanova, Alexandra Urban, William P. Welch, Jamie Joseph Van Gompel, Keith Starnes, David Spencer, Lia D. Ernst, Ushtar Amin, Angelica Rivera‐Cruz, Patricia Dugan, Marytery Fajardo, Matt Lallas, Barbara C. Jobst, Nicole Odom, Jarod L. Roland, Jon T. Willie, Sameer A. Sheth, Alica M. Goldman, Christopher T. Skidmore, Chengyuan Wu, Cornelia Drees, Jonathon Parker, Taneeta Mindy Ganguly, Jerzy Szaflarski, Saadi Ghatan, Lise Johnson, Jacob Norman, Brett Wingeier, Cairn G. Seale, Martha J. Morrell, Nautilus Study Group +47 morewiley +1 more sourceFactors associated with rapid pediatric acute seizure emergency treatment: Quality Improvement in Time to Treat Status Epilepticus baseline cohort
Epilepsia, EarlyView.Abstract Objective
Status epilepticus (SE) treatment is more effective when benzodiazepines (BZDs) are given soon after SE diagnosis. The Quality Improvement in Time to Treat Status Epilepticus (QuITT‐SE) trial is a multicenter, randomized, stepped‐wedge effectiveness‐implementation hybrid study aimed at improving time to SE treatment.Adam P. Ostendorf, Gabrielle Brown‐Mitchell, Tobias Loddenkemper, Lindsey A. Morgan, Brian Appavu, Raquel Farias‐Moeller, Dana Harrar, Craig Press, Janette Mailo, Nicholas S. Abend, William D. Gaillard, Shasha Bai, Mariah Eisner, Emily Kroshus, Kathryn Vannatta, Howard P. Goodkin, on behalf of the QuITT‐SE Study Group, Karen Allen, Megan Fredwall, Allison Nelson, Megan Rose, Corinne McCabe, Hannah Lehmann, Jared Haught, Lauren McHenry, William Korab, Amanda Courtney, Angela Turner, Coral Crandell, Sophie Rotter‐Aboyoun, Zoe Munsey, Mikaela Morales, Jacqueline Lee‐Eng, Sahar Rostamian, Elijah Simon, Luisa Fernanda Atunes Ortega, Alyssa Chen, Kristin Reid, Heather Kennedy, Courtney Englehardt, Jensen Kuchrawy, Abigail Howe, Nora Reilly, Lora Pixley, Amy Liljestrand, Annalee Antonetty, Agnieszka Kielian, Jennifer Gettings, Lillian Voke, Shannon Manzi, Lauren Fleser, Jeffrey Bolton, Madeline Chiujdea, Deborah Shiers, Michele Jackson, Stephanie Dailey, Lynn McDaniel, Jared Barkes, Brittany Dunn, Laure Cromwell, Irene Kelly, Kimberlee Meegan, Anne Vasiliadis, Julia S. Keenan, Sarah Vepraskas, Ronda Werner, Kimberly Zimmanck, Rupa Nallamothu, Sarah Otterson, Kaley Marrari, Lalaine Dungca, Nigel Negm, Sarah Kiel, Chris Kennie‐Richardson, Ariel Hierhozer, Katherine Dyer, Meera Singavi, Molly Green, Nate Evans, Caitlin Keiter, Jessica Johnson, Sara Molisani, Darshana Parikh, Veronica Zielinkski, Rachael Huber, Brody Giblin, Allix Edsill, Jessica Zook +87 morewiley +1 more sourceProgress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development
Epilepsia, EarlyView.Abstract
This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell +7 morewiley +1 more sourceProgress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development
Epilepsia, EarlyView.Abstract
Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell +7 morewiley +1 more source
